LY-367,265

LY-367,265 is a drug of the tetrahydropyridinylindole group developed by Eli Lilly, which acts as both a potent and selective antagonist at the serotonin 5-HT_2A receptor, and also a selective serotonin reuptake inhibitor (SSRI). It has antidepressant effects in animal studies, reduces glutamate signalling in the brain and increases the analgesic effects of morphine.^[1][2][3]

LY-367,265

Identifiers
IUPAC name 1-(2-(4-(6-fluoro-1H-indol-3-yl)-5,6-dihydropyridin-1(2H)-yl)ethyl)-1,4,5,6-tetrahydro-[1,2,5]thiadiazolo[4,3,2-ij]quinoline 2,2-dioxide
CAS Number	210751-39-6
PubChem CID	4605800
ChemSpider	3797242
UNII	SS58UXZ8ZU
ChEBI	CHEBI:183634
CompTox Dashboard (EPA)	DTXSID801017165
Chemical and physical data
Formula	C24H25FN4O2S
Molar mass	452.55 g·mol−1
3D model (JSmol)	Interactive image
SMILES FC1=CC=C2C(NC=C2C3=CCN(CCN(S4(=O)=O)C5=C6C(CCCN46)=CC=C5)CC3)=C1
InChI InChI=1S/C24H25FN4O2S/c25-19-6-7-20-21(16-26-22(20)15-19)17-8-11-27(12-9-17)13-14-28-23-5-1-3-18-4-2-10-29(24(18)23)32(28,30)31/h1,3,5-8,15-16,26H,2,4,9-14H2 Key:BJIPVHLRWSDKOS-UHFFFAOYSA-N

See also

• Tetrahydropyridinylindole